Brief: Kezar Life Sciences Presents Positive Complete Results From Mid-Stage Trial In Lupus Nephritis

Kezar Life Sciences

14/11/2022 13:17

Nov 14 (Reuters) - Kezar Life Sciences Inc  KZR.O :
    * KEZAR LIFE SCIENCES PRESENTS POSITIVE COMPLETE RESULTS
FROM THE
MISSION PHASE 2 TRIAL EVALUATING ZETOMIPZOMIB IN LUPUS NEPHRITIS
AT THE AMERICAN COLLEGE OF RHEUMATOLOGY CONVERGENCE 2022
    * KEZAR LIFE SCIENCES INC - ZETOMIPZOMIB ONCE-WEEKLY
CONTINUES TO
DEMONSTRATE A FAVORABLE SAFETY AND TOLERABILITY PROFILE
    * KEZAR LIFE SCIENCES - ADVERSE EVENTS WERE GENERALLY
MILD-TO-MODERATE
    * KEZAR LIFE SCIENCES INC - ORR INCREASED FROM 11 OF 17
PATIENTS
(64.7%) AT END OF TREATMENT TO 15 OF 17 PATIENTS (88.2%) AT END
OF STUDY

Source text for Eikon:  ID:nBwb5nylHa 
Further company coverage:  KZR.O 
 ((Reuters.Briefs@thomsonreuters.com;))